Current management of follicular lymphomas.

Item

http://www.wikidata.org/entity/Q36639053

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Current management of follicular lymphomas.

@ast

Current management of follicular lymphomas.

@en

type

Item

label

Current management of follicular lymphomas.

@ast

Current management of follicular lymphomas.

@en

prefLabel

Current management of follicular lymphomas.

@ast

Current management of follicular lymphomas.

@en

P1476

Current management of follicular lymphomas.

@en

P2093

Christian Buske

http://www.w3.org/2001/XMLSchema#string

Georg Lenz

http://www.w3.org/2001/XMLSchema#string

Martin Dreyling

http://www.w3.org/2001/XMLSchema#string

Michael Unterhalt

http://www.w3.org/2001/XMLSchema#string

Oliver Weigert

http://www.w3.org/2001/XMLSchema#string

Wolfgang Hiddemann

http://www.w3.org/2001/XMLSchema#string

P2860

Tobacco smoking, alcohol drinking and non-Hodgkin's lymphoma: A European multicenter case-control study (Epilymph)

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

P304

191-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2006.06378.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6722334

http://www.w3.org/2001/XMLSchema#string

P698

17073892

http://www.w3.org/2001/XMLSchema#string